TO: ALL PRINCIPAL INVESTIGATORS, NURSES, AND DATA MANAGERS

FROM: NRG-DT001 Study Chair
Meng Welliver, MD, PhD

DATE: September 10, 2021

RE: PROTOCOL NRG-DT001 – Cohort A, Dose Level 3 (Expansion Cohort): Temporarily Closed to Accrual

**Cohort A, Dose Level 3 (Expansion Cohort) Temporarily Closed to Accrual**

Cohort A (extremity/body wall) of NRG-DT001, “A Phase IB Trial of Neoadjuvant AMG 232 (KRT-232) Concurrent with Preoperative Radiotherapy in Wild-Type p53 Soft Tissue Sarcoma (STS),” is temporarily closed to accrual **effectively immediately** because 5 wild-type p53 patients have been enrolled to the expansion cohort (Dose Level 3), which is the maximum allowed per the protocol-specified design.

Cohort A, Dose Level 3 (Expansion Cohort) will remain temporarily closed for approximately 3 months until all patients complete the DLT evaluation period. NRG Oncology will send a broadcast with more details regarding reopening it to accrual or permanently closing it to accrual, depending on the data from patients still on the DLT observation period.

**Note: Cohort B (abdomen/pelvis/retroperitoneum) remains open to accrual to Dose Level 2.**

Please distribute this information to the appropriate personnel.